Evaluating the Efficacy and Safety of Transitioning Patients From Natalizumab to Ocrelizumab

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 20 Dec 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ocrelizumab (Primary) ; Natalizumab
Indications Multiple sclerosis
Focus Therapeutic Use
Acronyms OCTAVE

Most Recent Events

28 Oct 2022 Results assessing the efficacy and safety of transitioning patients from natalizumab to ocrelizumab presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
19 May 2021 Planned End Date changed from 1 Jun 2022 to 1 Dec 2021.
19 May 2021 Status changed from recruiting to active, no longer recruiting.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight